The dynamic regulation of PD-L1 expression could explain clinical cases showing that patients diagnosed as tumor PD-L1 negative show objective responses to atezolizumab (an anti-PD-L1 antibody) as a second-line treatment [21]. Here, CD274 is linked to neoplasm.